Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ACP1 | P24666 | 2/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | USP1 | O94782 | 1/20 | 0.44 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30530531 | 1.00 | EGFR (0.55) | EGFRPOLBNR2F2HTTSMN1; SMN2 | |
| SCHEMBL31178648 | 0.85 | EGFR (0.55) | EGFRPOLBNR2F2HTTMEN1 | |
| SCHEMBL17524354 | 0.77 | EGFR (0.61) | EGFRPOLBNR2F2HTTSMN1; SMN2 | |
| SCHEMBL7666360 | 0.76 | EGFR (0.58) | EGFRPOLBNR2F2MEN1KMT2A | |
| SCHEMBL13351975 | 0.76 | NPC1 (0.52) | EGFRPOLBNR2F2SMN1; SMN2ALDH1A1 | |
| SCHEMBL29532797 | 0.76 | PARP1 (0.47) | EGFRPOLBNR2F2SMN1; SMN2ALDH1A1 | |
| SCHEMBL24317490 | 0.76 | PARP1 (0.47) | EGFRPOLBNR2F2SMN1; SMN2ALDH1A1 | |
| SCHEMBL17524355 | 0.74 | EGFR (0.70) | EGFRPOLBNR2F2HTTALDH1A1 | |
| SCHEMBL24317491 | 0.74 | PDE4A (0.41) | EGFRNR2F2SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL25234461 | 0.72 | HTT (0.57) | EGFRPOLBNR2F2HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| CN-116723839-A | Tricyclic heterobifunctional compounds for degrading target proteins | C4医药公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-116457339-A | Tricyclic compounds degrading novel substrates for medical treatment | C4医药公司 | 2023-07-18 | — | — | CN | disclosed |
| WO-2022081928-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | EGFR 352/4885POLB 3831/4885NR2F2 2413/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | EGFR 64/4885POLB 469/4885NR2F2 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.